Inventiva announces full exercise of Underwriters' Option, bringing proceeds of Offering to approximately $172.5M

Core Points - Inventiva, a clinical-stage biopharmaceutical company, announced the full exercise of the underwriters' option in its public offering, resulting in a total of 44,805,193 American Depositary Shares (ADSs) issued, generating gross proceeds of approximately $172.5 million (€149.0 million) [1][2] - The offering price was set at $3.85 per ADS, which corresponds to €3.33 per ordinary share, reflecting a discount of 0.89% from the volume-weighted average price [4] - The net proceeds from the offering will be approximately $161.2 million (€139.3 million) after deducting underwriting fees and expenses, and these funds will be allocated on a pro rata basis to the intended uses identified in the base offering [2][3] Company Overview - Inventiva focuses on developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH) and is currently evaluating lanifibranor in a pivotal Phase 3 clinical trial [8] - The company is publicly listed on both Euronext Paris and the Nasdaq Global Market under the ticker symbol "IVA" [4][9]